BACKGROUND With the rapid development of haploidentical hematopoietic stem cell transplantation(haplo-HSCT),primary poor graft function(PGF)has become a lifethreatening complication.Effective therapies for PGF are inc...BACKGROUND With the rapid development of haploidentical hematopoietic stem cell transplantation(haplo-HSCT),primary poor graft function(PGF)has become a lifethreatening complication.Effective therapies for PGF are inconclusive.New Chinese patent medicine Pai-Neng-Da(PND)Capsule exerts dual effect in promoting hematopoiesis recovery and regulating immunity.Still,the application of PND capsule in hematopoietic stem cell transplantation,especially in the haplo-HSCT setting,has not yet been reported.AIM To evaluate the role of PND capsule in acute leukemia patients with haplo-HSCT.METHODS We retrospectively collected data of acute leukemia patients who underwent haplo-HSCT at the Affiliated People’s Hospital of Ningbo University between April 1,2015 and June 30,2020.Twenty-nine consecutive patients received oral PND capsule from the sixth day to the first month after haplo-HSCT were included in the PND group.In addition,31 patients who did not receive PND capsule during haplo-HSCT were included in the non-PND group.Subsequently,we compared the therapeutic efficacy according to the western medical evaluation indexes and Chinese medical symptom scores,and the survival between the PND group and the non-PND group,using the chi-square test,Fisher’s exact test,and the Kaplan-Meier method.RESULTS The duration of platelet engraftment was shorter in the PND group than in the non-PND group(P=0.039).The PND group received a lower frequency of red blood cells and platelet transfusions than the non-PND group(P=0.033 and P=0.035,respectively).In addition,PND capsule marginally reduced the rate of PGF(P=0.027)and relapse(P=0.043).After 33(range,4-106)months of follow-up,the 3-year relapse-free survival(P=0.046)and progression-free survival(P=0.049)were improved in the PND group than in the non-PND group.Also,the therapeutic efficacy of the PND group according to Chinese medical symptom scores was significantly better than that of the non-PND group(P=0.022).Moreover,the adverse events caused by PND capsule were mild.Nevertheless,there were no significant differences in the duration of neutrophil engraftment,the risk of infection within 100 days after haplo-HSCT,the acute graft-versus-host disease,or the 3-year overall survival between the two groups.CONCLUSION PND capsule could promote hematopoiesis reconstitution,improve the therapeutic efficacy of Chinese medical symptom scores,present anti-tumor effectiveness,and prolong the survival of acute leukemia patients with haplo-HSCT.展开更多
Chronic primary immune thrombocytopenia(CITP) is the most common acquired autoimmune disease that seriously threaten the physical and mental health of patients. Compared with Western medicine treatment, the interventi...Chronic primary immune thrombocytopenia(CITP) is the most common acquired autoimmune disease that seriously threaten the physical and mental health of patients. Compared with Western medicine treatment, the intervention and treatment of Chinese medicine(CM) has shown certain therapeutic advantages. This paper reviewed the new pathogenesis progress on T cell immune abnormality in CITP, and CM studies on interferes effects of cellular immune regulation of CITP in recent years. Qi deficiency failing to control blood and internal obstruction of blood stasis are the two common types of CM syndromes in CITP patients, the corresponding treatments include invigorating Pi(Spleen), supplementing qi, activating blood, as well as tonifying qi and activating yang, regulating Gan(Liver) to invigorate Pi. The authors also mentioned the problems in the research field of CM for CTIP treatment, and put forward new ideas for the research in the future.展开更多
Objective:To investigate the effects of panaxadiol saponins component(PDS-C) isolated from total saponins of panax ginseng on proliferation,differentiation and corresponding gene expression profile of megakaryocytes.M...Objective:To investigate the effects of panaxadiol saponins component(PDS-C) isolated from total saponins of panax ginseng on proliferation,differentiation and corresponding gene expression profile of megakaryocytes.Methods:Bone marrow culture of colony forming assay of megakaryocytic progenitor cells(CFU-MK) was observed for the promoting proliferation mediated by PDS-C,and differentiation of megakaryocytic blasts caused by PDS-C was analyzed with flow cytometry in CHRF-288 and Meg-01 cells,as well as proliferation,differentiation-related genes expression profile and protein expression levels were detected by human gene expression microarray and western blot.Results:In response to PDS-C 10,20 and 50 mg/L,CFU-MK from 10 human bone marrow samples was increased by 28.9%±2.7%,41.0%±3.2%and 40.5%±2.6%over untreated control,respectively(P<0.01,each).Flow cytometry analysis showed that PDS-C treated CHRF-288 cells and Meg-01 cells significantly increased in CD42 b,CD41,TSP and CD36 positive ratio,respectively.PDS-C induced29 genes up-regulated more than two-fold commonly in both cells detected by human expression microarray representing 4000 known genes.The protein expression levels of ZNF91,c-Fos,BTF3 a,GATA-1,RGS2,NDRG2 and RUNX1 were increased with western blot in correspond to microarray results.Conclusion:PDS-C as an effective component for hematopoiesis,play the role to enhance proliferation and differentiation of megakaryocytes,also up-regulated expression of proliferation,differentiation-related genes and proteins in vitro.展开更多
Objective:To investigate the potential efficacy of panaxadiol saponins component(PDS-C),a biologically active fraction isolated from total ginsenosides,to reverse chemotherapy-induced myelosuppression and pancytopenia...Objective:To investigate the potential efficacy of panaxadiol saponins component(PDS-C),a biologically active fraction isolated from total ginsenosides,to reverse chemotherapy-induced myelosuppression and pancytopenia caused by cyclophamide(CTX).Methods:Mice with myelosuppression induced by CTX were treated with PDS-C at a low-(20 mg/kg),moderate-(40 mg/kg),or high-dose(80 mg/kg) for 7 consecutive days.The level of peripheral white blood cell(WBC),neutrophil(NEU) and platelet(PLT) were measured,the histopathology and colony formation were observed,the protein kinase and transcription factors in hematopoietic cells were determined by immunohistochemical staining and Western blot.Results:In response to PDS-C therapy,the peripheral WBC,NEU and PLT counts of CTX-induced myelosuppressed mice were significantly increased in a dose-dependent manner.Similarly,bone marrow histopathology examination showed reversal of CTX-induced myelosuppression with increase in overall bone marrow cellularity and the number of hematopoietic cells(P<0.01).PDS-C also promoted proliferation of granulocytic and megakaryocyte progenitor cells in CTX-treated mice,as evidenced by significantly increase in colony formation units-granulocytes/monocytes and-megakaryocytes(P<0.01).The enhancement of hematopoiesis by PDS-C appears to be mediated by an intracellular signaling pathway,this was evidenced by the up-regulation of phosphorylated mitogen-activated protein kinase(p-MEK) and extracellular signal-regulated kinases(p-ERK),and receptor tyrosine kinase(C-kit) and globin transcription factor 1(GATA-1) in hematopoietic cells of CTX-treated mice(P<0.05).Conclusions:PDS-C possesses hematopoietic growth factor-like activities that promote proliferation and also possibly differentiation of hematopoietic progenitor cells in myelosuppressed mice,probably mediated by a mechanism involving MEK and ERK protein kinases,and C-kit and GATA-1 transcription factors.PDS-C may potentially be a novel treatment of myelosuppression and pancytopenia caused by chemotherapy.展开更多
Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(派能达胶囊t panaxadiol saponins component,PND),a new Chinese patent medicine,on patients with chronic aplastic anemia(CAA)and to explore the optimal...Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(派能达胶囊t panaxadiol saponins component,PND),a new Chinese patent medicine,on patients with chronic aplastic anemia(CAA)and to explore the optimal therapeutic regimen for CAA.Method:A total of 36 patients with CAA were enrolled and divided into three groups:the AP group(20 cases,andriol 120 mg/day + PND 240 mg/day),the ACP group(13 cases,andriol 120 mg/day + cyclosporine 3-6 mg·kd^(-1)·day^(-1) + PND 240 mg/day),and the PND group(3cases,PND 240 mg/day).All patients were treated and followed up for 6 months.Peripheral blood counts,renal and hepatic function and Chinese medical(CM) symptoms of patients were assessed and all indices were gathered at the beginning and end of the study.Result:In the AP group,no significant hematologic difference was observed at the end of 6-month treatment comparing with the beginning.In the ACP group,the blood counts were maintained at the same level after the 6-month treatment.In the PND group,trilineage hematologic improvement was displayed at the end of 6-month treatment comparing with the beginning.No significant difference was showed in renal and hepatic function in all patients.All patients' clinical symptom improved according to CM symptom score.The effective rates were 95%,73%and 100%,respectively.Conclusion:PND improved the efficacy and decreased side effects by cutting down the dosage of andriol,and it could also improve patients' clinical symptom and quality of life.PND were effective and safe in the treatment of CAA,it could be used alone or in combination with pharmacological agents such as andriol and cyclosporine.展开更多
Objective:To explore the effects of Danshen Injection(丹参注射液)on inhibition proliferation,inducing apoptosis and its possible mechanisms on human erythroid leukemic(HEL)cells.Methods:The commercial Chinese patent m...Objective:To explore the effects of Danshen Injection(丹参注射液)on inhibition proliferation,inducing apoptosis and its possible mechanisms on human erythroid leukemic(HEL)cells.Methods:The commercial Chinese patent medicine of Danshen Injection was extracted and isolated from Chinese herb of Salvia miltiorrhiza bung.The inhibition effects of proliferation were assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)method in HEL cells treated by Danshen Injection at various concentrations for 48 h.The cellular apoptosis was observed in morphology,analyzed by flow cytometry with annexin V and propidium iodide(PI)staining,and examined by DNA degradation ladder on agarose gel electrophoresis.Meanwhile,the expression levels of mutant Janus kinasez(JAK2)gene and phosphorylation-JAK2(P-JAK2)protein were detected by allele specific-polymerase chain reaction and Western blot.Results:The proliferation of HEL cells was effectively inhibited by Danshen Injection in a dose-dependent manner,with suppression rates from 19.46±2.31%to 50.20±5.21%.Typical apoptosis cells was observed in Danshen Injection treated HEL cells,the rates of annexin V positive cells increased obviously in a dose-dependent manner,as well as the DNA degradation ladder of apoptosis revealed on gel electrophoresis.The expression levels of mutant JAK2 gene and P-JAK2 protein reduced gradually with increasing dosage of Danshen injection.Conclusion:Danshen Injection could not only significantly inhibit the proliferation,but also induce apoptosis in HEL cells;down-regulation of the mutant JAK2 gene and P-JAK2 protein expressions are probably one of its molecular mechanisms.展开更多
Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies(HMs).Targeted therapy,aiming for DNA methylation,is an effective mainstay of modem medicine;however,many issues rema...Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies(HMs).Targeted therapy,aiming for DNA methylation,is an effective mainstay of modem medicine;however,many issues remain to be addressed.The progress of epigenetic studies and the proposed theory of"state-target medicine"have provided conditions to form a new treatment paradigm that combines the"body state adjustment"of CM with targeted therapy.We discussed the correlation between Chinese medicine(CM)syndromes/states and DNA methylation in this paper.Additionally,the latest research findings on the intervention and regulation of DNA methylation in HMs,including the core targets,therapy status,CM compounds and active components of the Chinese materia medica were concisely summarized to establish a theoretical foundation of"state-target synchronous conditioning"pattern of integrative medicine for HMs,simultaneously leading a new perspective in clinical diagnosis and therapy.展开更多
Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(panaxadiol saponins component,PNDC)in combination with the cyclosporine and androgen for patients with chronic aplastic anemia(CAA).Methods:A total ...Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(panaxadiol saponins component,PNDC)in combination with the cyclosporine and androgen for patients with chronic aplastic anemia(CAA).Methods:A total of 79 CAA patients was randomly divided into 2 groups by a random number table,including PCA group[43 cases,orally PNDC 320 mg/d plus cyclosporine 5 mg/(kg·d)plus andriol 80 mg/d]and CA group[36 cases,orally cyclosporine 5 mg/(kg·d)plus andriol 160 mg/d].All patients were treated and followed-up for 6 treatment courses over 24 weeks.The complete blood counts,score of Chinese medical(CM)symptoms were assessed and urine routine,electrocardiogram,hepatic and renal function were observed for safety evaluation.Female masculinization rating scale was established according to the actual clinical manifestations to evaluate the accurate degree of masculinization in female CAA patients treated by andriol.Results:The effective rates were 88.1%(37/42)in the PCA group and 77.8%(28/36)in the CA group based on the standard for the therapeutic efficacy evaluation of hematopathy.There was no significant difference in the white blood cell(WBC)counts,platelet counts and hemoglobin concentration of peripheral blood between two groups after 6 months treatment.The masculinization score of female patient in the PCA group was significantly lower than the CA group(P<0.05).The mild abdominal distention was observed in 1 case in the PCA group.In CA group,the abnormalities in the hepatic function developed in 2 cases and the renal disfunction was found in 1 case.Conclusion:The PNDC possesses certain curative effects in the treatment of CAA without obvious side-effects and can partially replace andriol thereby to reduce the degree of masculinization[Registried at Chinese Clinical Trial Registry(ChicTR1900028153)].展开更多
Objective: To investigate the potential efficacy of panaxadiol saponins component(PDS-C) in the treatment of aplastic anemia(AA) model mice. Methods: Totally 70 mice were divided into 7 groups as follows: normal, mode...Objective: To investigate the potential efficacy of panaxadiol saponins component(PDS-C) in the treatment of aplastic anemia(AA) model mice. Methods: Totally 70 mice were divided into 7 groups as follows: normal, model, low-, medium-, high-dose PDS-C(20, 40, 80 mg/kg, namely L-, M-, H-PDS-C), cyclosporine(40 mg/kg), and andriol(25 mg/kg) groups, respectively. An immune-mediated AA mouse model was established in BALB/c mice by exposing to 5.0 Gy total body irradiation at 1.0 Gy/min, and injecting with lymphocytes from DBA mice. On day 4 after establishment of AA model, all drugs were intragastrically administered daily for 15 days, respectively, while the mice in the normal and model groups were administered with saline solution. After treatment, the peripheral blood counts, bone marrow pathological examination, colony forming assay of bone marrow culture, T lymphocyte subpopulation analysis, as well as T-bet, GATA-3 and Fox P3 proteins were detected by flow cytometry and Western blot. Results: The peripheral blood of white blood cell(WBC), platelet, neutrophil counts and hemoglobin(Hb) concentration were significantly decreased in the model group compared with the normal group(all P<0.01). In response to 3 dose PDS-C treatment, the WBC, platelet, neutrophil counts were significantly increased at a dose-dependent manner compared with the model group(all P<0.01). The myelosuppression status of AA was significantly reduced in M-, H-PDS-C groups, and hematopoietic cell quantity of bone marrow was more abundant than the model group. The colony numbers of myeloid, erythroid and megakaryocytic progenitor cells in the model group were less than those of the normal mice in bone marrow culture, while, PDS-C therapy enhanced proliferation of hematopoietic progenitor cells by significantly increasing colony numbers(all P<0.01). Furthermore,PDS-C therapy increased peripheral blood CD3^+ and CD3^+CD4^+ cells and reduced CD3^+CD8^+ cells(P<0.05 or P<0.01). Meanwhile, PDS-C treatment at medium-and high doses groups also increased CD4^+CD25^+Fox P3^+ cells, downregulated T-bet protein expression, and upregulated GATA-3 and Fox P3 protein expressions in spleen cells(P<0.05). Conclusion: PDS-C possesses dual activities, promoting proliferation hematopoietic progenitor cells and modulating T lymphocyte immune functions in the treatment of AA model mice.展开更多
Graft-versus-host disease(GVHD)is the most common complication after allogeneic hematopoietic stem cell transplantation,and also an important factor affecting the survival and quality of life in patients after transpl...Graft-versus-host disease(GVHD)is the most common complication after allogeneic hematopoietic stem cell transplantation,and also an important factor affecting the survival and quality of life in patients after transplantation.Currently,immunosuppressive therapy is commonly used for GVHD,but the curative effect is not ideal.How to effectively prevent and treat GVHD is one of the difficulties to be solved urgently in the field of transplantation.In this paper,we summarize the latest progress in pathogenesis,prevention and treatment of GVHD with Chinese medicine(CM).We hope it will provide ideas and methods for exploring the mechanism and establishing a new comprehensive therapy for GVHD with CM.展开更多
基金Supported by The Zhejiang Provincial Science and Technology Program of Traditional Chinese Medicine,No.2017ZA129 and No.2018ZA112.
文摘BACKGROUND With the rapid development of haploidentical hematopoietic stem cell transplantation(haplo-HSCT),primary poor graft function(PGF)has become a lifethreatening complication.Effective therapies for PGF are inconclusive.New Chinese patent medicine Pai-Neng-Da(PND)Capsule exerts dual effect in promoting hematopoiesis recovery and regulating immunity.Still,the application of PND capsule in hematopoietic stem cell transplantation,especially in the haplo-HSCT setting,has not yet been reported.AIM To evaluate the role of PND capsule in acute leukemia patients with haplo-HSCT.METHODS We retrospectively collected data of acute leukemia patients who underwent haplo-HSCT at the Affiliated People’s Hospital of Ningbo University between April 1,2015 and June 30,2020.Twenty-nine consecutive patients received oral PND capsule from the sixth day to the first month after haplo-HSCT were included in the PND group.In addition,31 patients who did not receive PND capsule during haplo-HSCT were included in the non-PND group.Subsequently,we compared the therapeutic efficacy according to the western medical evaluation indexes and Chinese medical symptom scores,and the survival between the PND group and the non-PND group,using the chi-square test,Fisher’s exact test,and the Kaplan-Meier method.RESULTS The duration of platelet engraftment was shorter in the PND group than in the non-PND group(P=0.039).The PND group received a lower frequency of red blood cells and platelet transfusions than the non-PND group(P=0.033 and P=0.035,respectively).In addition,PND capsule marginally reduced the rate of PGF(P=0.027)and relapse(P=0.043).After 33(range,4-106)months of follow-up,the 3-year relapse-free survival(P=0.046)and progression-free survival(P=0.049)were improved in the PND group than in the non-PND group.Also,the therapeutic efficacy of the PND group according to Chinese medical symptom scores was significantly better than that of the non-PND group(P=0.022).Moreover,the adverse events caused by PND capsule were mild.Nevertheless,there were no significant differences in the duration of neutrophil engraftment,the risk of infection within 100 days after haplo-HSCT,the acute graft-versus-host disease,or the 3-year overall survival between the two groups.CONCLUSION PND capsule could promote hematopoiesis reconstitution,improve the therapeutic efficacy of Chinese medical symptom scores,present anti-tumor effectiveness,and prolong the survival of acute leukemia patients with haplo-HSCT.
基金Supported by the National Natural Science Foundation of China (No.30271597)Australia-China Institutional Links Research Program by International Development Program of Education Australia(No.IDP 2-8)+1 种基金Science and Technology Foundation of Zhjiang Province,China(No.2004C23002)Natural Science Foundation of Zhjiang Province,China(No.ZD0007)
基金Supported by the National Natural Science Foundation of China(No.81774068)National Major Project for the Innovative New Drugs of "the 13th Five-year Plan"(No.2016ZX09101071)
文摘Chronic primary immune thrombocytopenia(CITP) is the most common acquired autoimmune disease that seriously threaten the physical and mental health of patients. Compared with Western medicine treatment, the intervention and treatment of Chinese medicine(CM) has shown certain therapeutic advantages. This paper reviewed the new pathogenesis progress on T cell immune abnormality in CITP, and CM studies on interferes effects of cellular immune regulation of CITP in recent years. Qi deficiency failing to control blood and internal obstruction of blood stasis are the two common types of CM syndromes in CITP patients, the corresponding treatments include invigorating Pi(Spleen), supplementing qi, activating blood, as well as tonifying qi and activating yang, regulating Gan(Liver) to invigorate Pi. The authors also mentioned the problems in the research field of CM for CTIP treatment, and put forward new ideas for the research in the future.
基金Supported by National Natural Science Foundation of China(No.81373876)Zhejiang Provincial Natural Science Foundation(No.LY14H290004)Science and Technology Program of Zhejiang Province(No.2010C33098)
文摘Objective:To investigate the effects of panaxadiol saponins component(PDS-C) isolated from total saponins of panax ginseng on proliferation,differentiation and corresponding gene expression profile of megakaryocytes.Methods:Bone marrow culture of colony forming assay of megakaryocytic progenitor cells(CFU-MK) was observed for the promoting proliferation mediated by PDS-C,and differentiation of megakaryocytic blasts caused by PDS-C was analyzed with flow cytometry in CHRF-288 and Meg-01 cells,as well as proliferation,differentiation-related genes expression profile and protein expression levels were detected by human gene expression microarray and western blot.Results:In response to PDS-C 10,20 and 50 mg/L,CFU-MK from 10 human bone marrow samples was increased by 28.9%±2.7%,41.0%±3.2%and 40.5%±2.6%over untreated control,respectively(P<0.01,each).Flow cytometry analysis showed that PDS-C treated CHRF-288 cells and Meg-01 cells significantly increased in CD42 b,CD41,TSP and CD36 positive ratio,respectively.PDS-C induced29 genes up-regulated more than two-fold commonly in both cells detected by human expression microarray representing 4000 known genes.The protein expression levels of ZNF91,c-Fos,BTF3 a,GATA-1,RGS2,NDRG2 and RUNX1 were increased with western blot in correspond to microarray results.Conclusion:PDS-C as an effective component for hematopoiesis,play the role to enhance proliferation and differentiation of megakaryocytes,also up-regulated expression of proliferation,differentiation-related genes and proteins in vitro.
基金Supported by the Science and Technology Program Project of Zhejiang Province(No.2015C33173)Chinese Medicine Foundation of Young Talents in Zhejiang Province(No.2014ZQ006)Australia-China Institutional Links Research Program sponsored by the International Development Program of Education Australia(No.IDP 2-8)
文摘Objective:To investigate the potential efficacy of panaxadiol saponins component(PDS-C),a biologically active fraction isolated from total ginsenosides,to reverse chemotherapy-induced myelosuppression and pancytopenia caused by cyclophamide(CTX).Methods:Mice with myelosuppression induced by CTX were treated with PDS-C at a low-(20 mg/kg),moderate-(40 mg/kg),or high-dose(80 mg/kg) for 7 consecutive days.The level of peripheral white blood cell(WBC),neutrophil(NEU) and platelet(PLT) were measured,the histopathology and colony formation were observed,the protein kinase and transcription factors in hematopoietic cells were determined by immunohistochemical staining and Western blot.Results:In response to PDS-C therapy,the peripheral WBC,NEU and PLT counts of CTX-induced myelosuppressed mice were significantly increased in a dose-dependent manner.Similarly,bone marrow histopathology examination showed reversal of CTX-induced myelosuppression with increase in overall bone marrow cellularity and the number of hematopoietic cells(P<0.01).PDS-C also promoted proliferation of granulocytic and megakaryocyte progenitor cells in CTX-treated mice,as evidenced by significantly increase in colony formation units-granulocytes/monocytes and-megakaryocytes(P<0.01).The enhancement of hematopoiesis by PDS-C appears to be mediated by an intracellular signaling pathway,this was evidenced by the up-regulation of phosphorylated mitogen-activated protein kinase(p-MEK) and extracellular signal-regulated kinases(p-ERK),and receptor tyrosine kinase(C-kit) and globin transcription factor 1(GATA-1) in hematopoietic cells of CTX-treated mice(P<0.05).Conclusions:PDS-C possesses hematopoietic growth factor-like activities that promote proliferation and also possibly differentiation of hematopoietic progenitor cells in myelosuppressed mice,probably mediated by a mechanism involving MEK and ERK protein kinases,and C-kit and GATA-1 transcription factors.PDS-C may potentially be a novel treatment of myelosuppression and pancytopenia caused by chemotherapy.
基金Supported by the Science and Technology Program of Zhejiang Province,China(Public Welfare Technology Applied Research,No.2010C33098)Science and Technology Division of Jinhua Municipal Government(No.11-3-013)
文摘Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(派能达胶囊t panaxadiol saponins component,PND),a new Chinese patent medicine,on patients with chronic aplastic anemia(CAA)and to explore the optimal therapeutic regimen for CAA.Method:A total of 36 patients with CAA were enrolled and divided into three groups:the AP group(20 cases,andriol 120 mg/day + PND 240 mg/day),the ACP group(13 cases,andriol 120 mg/day + cyclosporine 3-6 mg·kd^(-1)·day^(-1) + PND 240 mg/day),and the PND group(3cases,PND 240 mg/day).All patients were treated and followed up for 6 months.Peripheral blood counts,renal and hepatic function and Chinese medical(CM) symptoms of patients were assessed and all indices were gathered at the beginning and end of the study.Result:In the AP group,no significant hematologic difference was observed at the end of 6-month treatment comparing with the beginning.In the ACP group,the blood counts were maintained at the same level after the 6-month treatment.In the PND group,trilineage hematologic improvement was displayed at the end of 6-month treatment comparing with the beginning.No significant difference was showed in renal and hepatic function in all patients.All patients' clinical symptom improved according to CM symptom score.The effective rates were 95%,73%and 100%,respectively.Conclusion:PND improved the efficacy and decreased side effects by cutting down the dosage of andriol,and it could also improve patients' clinical symptom and quality of life.PND were effective and safe in the treatment of CAA,it could be used alone or in combination with pharmacological agents such as andriol and cyclosporine.
基金Supported by Zhejiang Province Administration of Traditional Chinese Medicine(No.2010ZA120)Zhejiang Provincial Natural Science Foundation of China(No.Y207632)
文摘Objective:To explore the effects of Danshen Injection(丹参注射液)on inhibition proliferation,inducing apoptosis and its possible mechanisms on human erythroid leukemic(HEL)cells.Methods:The commercial Chinese patent medicine of Danshen Injection was extracted and isolated from Chinese herb of Salvia miltiorrhiza bung.The inhibition effects of proliferation were assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)method in HEL cells treated by Danshen Injection at various concentrations for 48 h.The cellular apoptosis was observed in morphology,analyzed by flow cytometry with annexin V and propidium iodide(PI)staining,and examined by DNA degradation ladder on agarose gel electrophoresis.Meanwhile,the expression levels of mutant Janus kinasez(JAK2)gene and phosphorylation-JAK2(P-JAK2)protein were detected by allele specific-polymerase chain reaction and Western blot.Results:The proliferation of HEL cells was effectively inhibited by Danshen Injection in a dose-dependent manner,with suppression rates from 19.46±2.31%to 50.20±5.21%.Typical apoptosis cells was observed in Danshen Injection treated HEL cells,the rates of annexin V positive cells increased obviously in a dose-dependent manner,as well as the DNA degradation ladder of apoptosis revealed on gel electrophoresis.The expression levels of mutant JAK2 gene and P-JAK2 protein reduced gradually with increasing dosage of Danshen injection.Conclusion:Danshen Injection could not only significantly inhibit the proliferation,but also induce apoptosis in HEL cells;down-regulation of the mutant JAK2 gene and P-JAK2 protein expressions are probably one of its molecular mechanisms.
基金Supported by the National Natural Science Foundation of China(No.81774068)the Natural Science Foundation of Zhejiang Province(No.LY20H290004)Youth Project of the Natural Science Foundation of Zhejiang Province(No.LQ19H290002)。
文摘Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies(HMs).Targeted therapy,aiming for DNA methylation,is an effective mainstay of modem medicine;however,many issues remain to be addressed.The progress of epigenetic studies and the proposed theory of"state-target medicine"have provided conditions to form a new treatment paradigm that combines the"body state adjustment"of CM with targeted therapy.We discussed the correlation between Chinese medicine(CM)syndromes/states and DNA methylation in this paper.Additionally,the latest research findings on the intervention and regulation of DNA methylation in HMs,including the core targets,therapy status,CM compounds and active components of the Chinese materia medica were concisely summarized to establish a theoretical foundation of"state-target synchronous conditioning"pattern of integrative medicine for HMs,simultaneously leading a new perspective in clinical diagnosis and therapy.
基金Supported by Research Foundation of Chinese Medicine Program of Zhejiang Province(No.2015ZA211)National Major Project for the Innovative New Drugs of"the 13th Five-Year Plan"(No.2016ZX09101071)。
文摘Objective:To evaluate the efficacy and safety of Pai-Neng-Da Capsule(panaxadiol saponins component,PNDC)in combination with the cyclosporine and androgen for patients with chronic aplastic anemia(CAA).Methods:A total of 79 CAA patients was randomly divided into 2 groups by a random number table,including PCA group[43 cases,orally PNDC 320 mg/d plus cyclosporine 5 mg/(kg·d)plus andriol 80 mg/d]and CA group[36 cases,orally cyclosporine 5 mg/(kg·d)plus andriol 160 mg/d].All patients were treated and followed-up for 6 treatment courses over 24 weeks.The complete blood counts,score of Chinese medical(CM)symptoms were assessed and urine routine,electrocardiogram,hepatic and renal function were observed for safety evaluation.Female masculinization rating scale was established according to the actual clinical manifestations to evaluate the accurate degree of masculinization in female CAA patients treated by andriol.Results:The effective rates were 88.1%(37/42)in the PCA group and 77.8%(28/36)in the CA group based on the standard for the therapeutic efficacy evaluation of hematopathy.There was no significant difference in the white blood cell(WBC)counts,platelet counts and hemoglobin concentration of peripheral blood between two groups after 6 months treatment.The masculinization score of female patient in the PCA group was significantly lower than the CA group(P<0.05).The mild abdominal distention was observed in 1 case in the PCA group.In CA group,the abnormalities in the hepatic function developed in 2 cases and the renal disfunction was found in 1 case.Conclusion:The PNDC possesses certain curative effects in the treatment of CAA without obvious side-effects and can partially replace andriol thereby to reduce the degree of masculinization[Registried at Chinese Clinical Trial Registry(ChicTR1900028153)].
基金Supported by the National Natural Science Foundation of China(No.81774068)Medical and Health Key Project of Zhejiang Province(No.2011ZDA021)Zhejiang Provincial Natural Science Foundation of China(No.LY14H280004)
文摘Objective: To investigate the potential efficacy of panaxadiol saponins component(PDS-C) in the treatment of aplastic anemia(AA) model mice. Methods: Totally 70 mice were divided into 7 groups as follows: normal, model, low-, medium-, high-dose PDS-C(20, 40, 80 mg/kg, namely L-, M-, H-PDS-C), cyclosporine(40 mg/kg), and andriol(25 mg/kg) groups, respectively. An immune-mediated AA mouse model was established in BALB/c mice by exposing to 5.0 Gy total body irradiation at 1.0 Gy/min, and injecting with lymphocytes from DBA mice. On day 4 after establishment of AA model, all drugs were intragastrically administered daily for 15 days, respectively, while the mice in the normal and model groups were administered with saline solution. After treatment, the peripheral blood counts, bone marrow pathological examination, colony forming assay of bone marrow culture, T lymphocyte subpopulation analysis, as well as T-bet, GATA-3 and Fox P3 proteins were detected by flow cytometry and Western blot. Results: The peripheral blood of white blood cell(WBC), platelet, neutrophil counts and hemoglobin(Hb) concentration were significantly decreased in the model group compared with the normal group(all P<0.01). In response to 3 dose PDS-C treatment, the WBC, platelet, neutrophil counts were significantly increased at a dose-dependent manner compared with the model group(all P<0.01). The myelosuppression status of AA was significantly reduced in M-, H-PDS-C groups, and hematopoietic cell quantity of bone marrow was more abundant than the model group. The colony numbers of myeloid, erythroid and megakaryocytic progenitor cells in the model group were less than those of the normal mice in bone marrow culture, while, PDS-C therapy enhanced proliferation of hematopoietic progenitor cells by significantly increasing colony numbers(all P<0.01). Furthermore,PDS-C therapy increased peripheral blood CD3^+ and CD3^+CD4^+ cells and reduced CD3^+CD8^+ cells(P<0.05 or P<0.01). Meanwhile, PDS-C treatment at medium-and high doses groups also increased CD4^+CD25^+Fox P3^+ cells, downregulated T-bet protein expression, and upregulated GATA-3 and Fox P3 protein expressions in spleen cells(P<0.05). Conclusion: PDS-C possesses dual activities, promoting proliferation hematopoietic progenitor cells and modulating T lymphocyte immune functions in the treatment of AA model mice.
基金Supported by the National Natural Science Foundation of China(No.81774068)the Natural Science Foundation of Zhejiang Province(Youth Project,No.LQ19H290002)。
文摘Graft-versus-host disease(GVHD)is the most common complication after allogeneic hematopoietic stem cell transplantation,and also an important factor affecting the survival and quality of life in patients after transplantation.Currently,immunosuppressive therapy is commonly used for GVHD,but the curative effect is not ideal.How to effectively prevent and treat GVHD is one of the difficulties to be solved urgently in the field of transplantation.In this paper,we summarize the latest progress in pathogenesis,prevention and treatment of GVHD with Chinese medicine(CM).We hope it will provide ideas and methods for exploring the mechanism and establishing a new comprehensive therapy for GVHD with CM.
